Journal article

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

MM Regan, BA Walley, PA Francis, GF Fleming, I Lang, HL Gomez, M Colleoni, C Tondini, G Pinotti, M Salim, S Spazzapan, V Parmar, T Ruhstaller, EA Abdi, RD Gelber, AS Coates, A Goldhirsch, O Pagani

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2017

Abstract

Background: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation. Design and methods: We analyzed 1872 patients enrolled in the randomized phase III TEXT and SOFT trials who received adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer and upon randomization to an OFS-containing adjuvant endocrine therapy, initiated gonadotropin-releasing-hormone-agonist triptorelin. Breast cancer-free interval (BCFI) was compared between patients who ..

View full abstract

Grants

Awarded by US National Institutes of Health


Awarded by Breast Cancer Research Foundation [BCRF]


Awarded by Australia and New Zealand Breast Cancer Trials Group [National Health and Medical Research Council]


Awarded by SWOG [US National Institutes of Health]


Awarded by Alliance for Clinical Trials in Oncology [US National Institutes of Health]


Awarded by ECOG-ACRIN Cancer Research Group [US National Institutes of Health]


Awarded by NSABP/NRG Oncology [US National Institutes of Health]


Awarded by NCIC-CTG [US National Institutes of Health]


Awarded by Canadian Cancer Society Research Institute


Awarded by ICR-CTSU on behalf of the National Cancer Research Institute Breast Clinical Studies Group United Kingdom (NCRI-BCSG-ICR-CTSU) [Cancer Research UK]


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

TEXT and SOFT received financial support for trial conduct from Pfizer, the IBCSG and the US National Cancer Institute at the National Institutes of Health (NIH). Pfizer and Ipsen provided drug supply. The pharmaceutical companies have no role in the reporting or interpretation of the trials, other than a minority representation on the Steering Committee. Support for the coordinating group, IBCSG: Frontier Science and Technology Research Foundation [no grant number], Swiss Group for Clinical Cancer Research [SAKK; no grant number], Cancer Research Switzerland/Oncosuisse [no grant number], the Foundation for Clinical Cancer Research of Eastern Switzerland [OSKK; no grant number], US National Institutes of Health [grant number CA075362], Breast Cancer Research Foundation [BCRF; grant number 16-185]. Grant support of cooperative groups: Australia and New Zealand Breast Cancer Trials Group [National Health and Medical Research Council grant numbers 351161, 510788 and 1105058]; SWOG [US National Institutes of Health grant number CA32102]; Alliance for Clinical Trials in Oncology [US National Institutes of Health grant number CA180821]; ECOG-ACRIN Cancer Research Group [US National Institutes of Health grant numbers CA21115, CA16116]; NSABP/NRG Oncology [US National Institutes of Health grant numbers U10-CA12027, U10-CA69651, U10-CA37377, U10-CA69974]; NCIC-CTG [US National Institutes of Health grant number CA077202; and Canadian Cancer Society Research Institute grant numbers 015469, 021039]; ICR-CTSU on behalf of the National Cancer Research Institute Breast Clinical Studies Group United Kingdom (NCRI-BCSG-ICR-CTSU Partnership) [Cancer Research UK grant numbers CRUKE/03/022, CRUKE/03/023, A15955; National Institute for Health Research/Institute of Cancer Research Biomedical Research Centre (no grant number); National Institute for Health/Cambridge Biomedical Research Centre (no grant number)].